-
1
ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
Published 2025-01-01Subjects: Get full text
Article -
2
-
3
-
4
miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting
Published 2025-02-01Subjects: Get full text
Article -
5
Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
Published 2025-12-01Subjects: Get full text
Article -
6
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies
Published 2025-01-01Subjects: Get full text
Article -
7
Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges
Published 2025-01-01Subjects: Get full text
Article -
8
Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
Published 2025-01-01Subjects: Get full text
Article -
9